Pfizer Announces Positive Top-Line Results for Phase III Trial of Etrasimod in Ulcerative Colitis Patients

Pfizer, Inc. announced positive topline results from a Phase III study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate receptor modulator in development for the treatment of moderately to severely active ulcerative colitis.